Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biomarker deals

Biomarker deals

Caprion
Partner Deal description Date
Sunol Molecular Caprion received rights to develop antibodies in Phase I for hemolytic uremic syndrome (HUS) resulting from

Read the full 268 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE